Transaction #34162 · Form 4 · 0001193125-26-428010
CRISPR Therapeutics AG · Stock award · Restricted Stock Units
CRISPR Therapeutics AG · Transacted October 19, 2026 · Filed October 21, 2026
What does this filing report?
An SEC Form 4 filing for CRISPR Therapeutics AG records a stock award involving Restricted Stock Units on October 19, 2026. The reported quantity was 25,000. The filing date is October 21, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- CRISPR Therapeutics AG
- Company CIK
- 0001674416
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 25,000
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 25,000
- Ownership description
- Not reported
- SEC acceptance time
- Oct 21, 2026, 5:41 PM EDT
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Silver Andrew Jacob ↗
Chief Financial Officer
CIK 0002158786
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Shares
- Underlying quantity
- 25,000
- Conversion / exercise price
- Not reported
- Exercise date
- Not reported
- Expiration date
- Not reported
Filing footnotes & remarks
- F1
- Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- F2
- This restricted stock unit award was granted on October 19, 2026 with respect to 25,000 Common Shares, with 100% of the shares vesting on October 19, 2028.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.